Allergy Therapeutics PLC
LSE:AGY
Intrinsic Value
Allergy Therapeutics Plc is a biotechnology company. [ Read More ]
The intrinsic value of one
AGY
stock under the Base Case scenario is
1.87
GBX.
Compared to the current market price of 2.85 GBX,
Allergy Therapeutics PLC
is
Overvalued by 34%.
Allergy Therapeutics PLC's market capitalization is 135.8m GBX.
AGY stock price is 2.85 GBX.
AGY stock (1.87 GBX) is 34% less than its price (2.85 GBX).
AGY stock (2.69 GBX) is 6% less than its price (2.85 GBX). Open Relative Valuation
AGY has upside potential of 465% compared to the average analyst price target.
Open Wall St Estimates
AGY's short-term assets (35m GBP) exceed its short-term liabilties (25m GBP).
AGY's Revenue has dropped by 17% over the past 12 months.
AGY's long-term assets (69m GBP) exceed its long-term liabilties (43m GBP).
AGY's ROE (Return on Equity) has significantly decreased in the last 3 years from 12% to -156%.
AGY's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 19% to -104%.
AGY's Revenue has been falling by 13% per year for the last 3 years.
AGY has negative Net Debt. This means that the company has more cash and short-term investments (14m GBP) than debt (8m GBP).
AGY has negative Operating Income for the last twelve months.
AGY has negative Net Income for the last twelve months.
AGY's ROE (Return on Equity) for the past 12 months is negative and is equal to -156%.
AGY's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -104%.
AGY has positive Gross Profit for the last twelve months.
AGY's D/E (Debt to Equity) is very low and is equal to 0.31.
AGY has negative Free Cash Flow for the last twelve months.
AGY has negative three-year average ROE (Return on Equity): -65%. The company is not efficient at transforming stockholders' equity into net income.
AGY has negative three-year average ROIC (Return on Invested Capital): -43%. The company is not efficient at using invested capital to generate operating income.
AGY's Altman Z-Score is very low and is equal to -2.19.
AGY doesn't generate enough operating income (-39m GBP) to safely cover interest payments on its debt (4m GBP).
Valuation Backtest
Allergy Therapeutics PLC
Run backtest to discover the historical profit from buying and selling
AGY
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Allergy Therapeutics PLC
Balance Sheet Decomposition
Allergy Therapeutics PLC
| Current Assets | 35.3m |
| Cash & Short-Term Investments | 13.5m |
| Receivables | 9.9m |
| Other Current Assets | 11.9m |
| Non-Current Assets | 33.7m |
| Long-Term Investments | 5.3m |
| PP&E | 23.4m |
| Intangibles | 5m |
| Current Liabilities | 25.3m |
| Accounts Payable | 20.1m |
| Other Current Liabilities | 5.2m |
| Non-Current Liabilities | 17.3m |
| Long-Term Debt | 8.1m |
| Other Non-Current Liabilities | 9.2m |
Earnings Waterfall
Allergy Therapeutics PLC
|
Revenue
|
53.3m
GBP
|
|
Cost of Revenue
|
-25.3m
GBP
|
|
Gross Profit
|
28m
GBP
|
|
Operating Expenses
|
-66.8m
GBP
|
|
Operating Income
|
-38.8m
GBP
|
|
Other Expenses
|
-11.4m
GBP
|
|
Net Income
|
-50.2m
GBP
|
Free Cash Flow Analysis
Allergy Therapeutics PLC
AGY Profitability Score
Profitability Due Diligence
Allergy Therapeutics PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Allergy Therapeutics PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
AGY Solvency Score
Solvency Due Diligence
Allergy Therapeutics PLC's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Allergy Therapeutics PLC's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AGY Price Targets Summary
Allergy Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
AGY
is 16.11 GBX
.
Shareholder Return
AGY Price
Allergy Therapeutics PLC
| Average Annual Return | 20.11% |
| Standard Deviation of Annual Returns | 76.83% |
| Max Drawdown | -98% |
| Market Capitalization | 135.8m GBX |
| Shares Outstanding | 4 766 439 936 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Allergy Therapeutics PLC
Country
Industry
Market Cap
Dividend Yield
Description
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
Contact
IPO
Employees
Officers
The intrinsic value of one
AGY
stock under the Base Case scenario is
1.87
GBX.
Compared to the current market price of 2.85 GBX,
Allergy Therapeutics PLC
is
Overvalued by 34%.
You don't have any saved screeners yet
